Unique ID issued by UMIN | UMIN000051728 |
---|---|
Receipt number | R000059041 |
Scientific Title | Treatment Preference in Patients with NMOSD |
Date of disclosure of the study information | 2023/07/31 |
Last modified on | 2023/07/27 18:46:10 |
Treatment Preference in Patients with NMOSD
Treatment Preference in Patients with NMOSD
Treatment Preference in Patients with NMOSD
Treatment Preference in Patients with NMOSD
Japan |
Neuromyelitis Optica Spectrum Disorders
Neurology |
Others
NO
To structure the causal relationship between NMOSD patients' subjective adverse event experience and impact on daily life and to quantify treatment choices and preferences in NMOSD patients
Others
Patients' treatment preference
Causal Relationship between Subjective Adverse Event Experience and Impact on Daily Living of Patients with NMOSD
Subjective Adverse Event Experience and Importance of Impact on Daily Living of Patients with NMOSD
Others,meta-analysis etc
20 | years-old | <= |
Not applicable |
Male and Female
Subjects who meet all of the following criteria:
(1)Documented diagnosis of NMOSD
(2)Anti-aquaporin-4 antibody test positive
(3)Patients who are taking or have taken an oral steroid
(4)Patients aged 20 years or older at the time of enrollment
(5)Must have sufficient understanding to conduct the research (The patient may require assistance in reading aloud, etc. due to visual disturbance.)
(6)Individuals who have consented to participate in this research
(7)People who are living in Japan at the time of enrollment
(8)Individuals who have equipment/communication environment to apply for research participation online and perform interviews or respond to questionnaires
Subjects who meet any of the following criteria:
(1)Persons who have difficulty in obtaining consent or conducting this research due to a lack of Japanese ability
(2)People who cannot participate in the survey
30
1st name | KATSUHISA |
Middle name | |
Last name | YAMASHITA |
Chugai Pharmaceutical Co., Ltd.
Medical Affairs Div. Specialty Medical Science Dept.
1038324
1-1 Nihonbashi-Muromachi 2-chome, Nihonbashi Mitsui Tower (Reception15F) Chuo-ku, Tokyo
0332816611
cma-clinicaltrial@chugai-pharm.co.jp
1st name | TADASHI |
Middle name | |
Last name | NAGATSUKA |
Chugai Pharmaceutical Co., Ltd.
Medical Affairs Div. Specialty Medical Science Dept.
1038324
1-1 Nihonbashi-Muromachi 2-chome, Nihonbashi Mitsui Tower (Reception15F) Chuo-ku, Tokyo
0332816611
cma-clinicaltrial@chugai-pharm.co.jp
Chugai Pharmaceutical Co., Ltd.
Chugai Pharmaceutical Co., Ltd.
Profit organization
Non-Profit Organization MINS Institutional Review Board
5-20-9-401, Mita, Minato-ku, Tokyo 108-0073
03-6416-1868
npo-mins@j-irb.com
NO
2023 | Year | 07 | Month | 31 | Day |
Unpublished
Preinitiation
2023 | Year | 04 | Month | 17 | Day |
2023 | Year | 08 | Month | 03 | Day |
2023 | Year | 12 | Month | 31 | Day |
This study aims to clarify treatment selection factors in patients with NMOSD
2023 | Year | 07 | Month | 27 | Day |
2023 | Year | 07 | Month | 27 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/icdr_e/ctr_view.cgi?recptno=R000059041
Research Plan | |
---|---|
Registered date | File name |
Research case data specifications | |
---|---|
Registered date | File name |
Research case data | |
---|---|
Registered date | File name |